LTZ Therapeutics Secures $38 Million Financing to Advance Pioneering Myeloid Cell Engager (MCE) Immunotherapy Pipeline

May 06, 2026 22:42 CST Updated 22:42

LTZ Therapeutics

Immunotherapy Developer

On May 6, Redwood City, California, USA, and Shenzhen, China – LTZ Therapeutics (Zean An Biomedical), a clinical-stage biotechnology company focused on immunotherapy, announced the completion of a $38 million oversubscribed financing round to accelerate the development of its immunotherapy pipeline based on Universal Myeloid Cell Engager (U-MCE™), particularly its leading asset LTZ-301 for oncology and autoimmune diseases. This round of financing was led by Hillhouse Capital's venture arm.A large international sovereign wealth fund followed up with a significant investment, and multiple existing shareholders added to their investments, includingIncluding a global pharmaceutical giant, Boyu Venture Capital, 5Y Capital, BlueRun Ventures, Unicorn Capital, and Shunwei Capital.。Since its establishment in 2022, this financing has brought LTZ's total funding to approximately US$130 million.In this round of financing,LTZ TherapeuticsAppointment of Erin Lavelle asIndependent Director of the Company.

In April 2022, LTZ Therapeutics completed a $17 million Pre-A round of financing.K2 Venture Partners Leads, Qiming Venture Capital and Tigermed Participate. In May 2023, it completed a Pre-A+ round of financing exceeding 10 million US dollars, led by Qiming Venture Partners with Shunwei Capital participating. In July 2024, it completed another round exceeding$20 Million Series A Financing,Led by Longpan Investment, with participation from Gaoling Ventures, and additional investment from existing shareholders such as Qiming Venture Partners, K2VC, and Shunwei Capital. April 2025Completed$40 Million Series A+ Financing Round Led by Matrix Partners, with Participation from 5Y Capital, BlueRun Ventures, Uniquant Capital, and the Follicular Lymphoma Innovation Research Institute; Longpan Investment and GL Ventures Continue to Increase Their Investment.Previously,LTZ Therapeutics Inc. has successively reached strategic cooperation with two major multinational pharmaceutical companies, Eli Lilly and GSK, focusing on autoimmune diseases and the field of oncology, respectively.（$50 Million Upfront Payment! GSK Bets on LTZ Therapeutics' MCE Platform）

The proceeds from this round of financing will be used to accelerateLTZ TherapeuticsThe development of the product line supports the company's ongoing leading asset LTZ-301 in Phase 1 clinical trials, which is actively recruiting patients from multiple top clinical institutions in the United States, as well as the Investigational New Drug (IND) application and the second asset, LTZ-2.Phase 1 Clinical Trial Initiation for 32.LTZ-301 is a novel "myeloid cell engager" bispecific antibody that enhances the phagocytosis and efficient clearance of tumor cells by guiding macrophages and monocytes to target and eliminate CD79b-positive B cells.

LTZ TherapeuticsInnovationFounder and Chief ExecutiveOfficialLi JinzeBoThe scholar stated:"This financing allows us toThe“Myeloid Cell Connector”（MCE）Platform's"Potential is being translated into tangible clinical impact for patients. We are building strong momentum across our pipeline, and we are grateful for the strong support from high-quality investors, whose collaboration enables us to accelerate the development of innovative immunotherapies aimed at leveraging bone marrow biology to address significant unmet medical needs."

Dr. Jinze LiRepresentation："We are delighted to welcome Erin Lavelle to our board of directors at this critical growth stage. Erin brings over 25 years of executive experience in the pharmaceutical and biotechnology industries, spanning both private and public companies. Most recently, as Chief Operating Officer and Chief Financial Officer of Provention Bio, Ms. Lavelle led Genmab's $1.8 billion acquisition of the company, as well as the oversubscribed $112 million Series B financing round prior to the acquisition, and spearheaded the company’s preparation for going public. Erin’s addition to the LTZ Therapeutics board will be invaluable as we continue to advance our clinical pipeline and expand the company globally."

The project leader of Hillhouse Ventures stated:"GL Ventures is delighted to partner with LTZ Therapeutics as the company expands its novel proprietary U-MCE platform, harnessing the therapeutic potential of myeloid biology across multiple early-stage programs. The advancement of its lead asset LTZ-301 into Phase 1 clinical trials, along with the upcoming IND submission for LTZ-232, reflects the team's operational efficiency and ability to execute in this first-in-class model. We will continue to support Robert and his team in advancing this innovative platform to bring breakthrough treatment options to patients."

Ms. Erin Lavelle is an independent director of the company.Ms. Lavelle recently served as the Chief Financial Officer and Chief Operating Officer of Proforma Biologics. During her tenure,She successfully led the milestone transaction of Protagonist being acquired by Danish Genmab for $1.8 billion, as well as the oversubscribed $112 million Series B financing round prior to the acquisition., and take the lead in advancing the preparations for Putrue's market launch.

Follow the official account below to explore the world with you!